DZ2891A1 - Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number
DZ2891A1
DZ2891A1 DZ990191A DZ990191A DZ2891A1 DZ 2891 A1 DZ2891 A1 DZ 2891A1 DZ 990191 A DZ990191 A DZ 990191A DZ 990191 A DZ990191 A DZ 990191A DZ 2891 A1 DZ2891 A1 DZ 2891A1
Authority
DZ
Algeria
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
new substituted
tetrahydroquinoline derivatives
Prior art date
Application number
DZ990191A
Other languages
English (en)
Inventor
Michael Paul Deninno
George Tetteh
Magnus Aryitey
Roger Benjamin Ruggeri
Ronald Thure Wester
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2891A1 publication Critical patent/DZ2891A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DZ990191A 1998-09-17 1999-09-13 Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2891A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10092798P 1998-09-17 1998-09-17

Publications (1)

Publication Number Publication Date
DZ2891A1 true DZ2891A1 (fr) 2003-12-15

Family

ID=22282246

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990191A DZ2891A1 (fr) 1998-09-17 1999-09-13 Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (50)

Country Link
US (2) US6140343A (fr)
EP (1) EP1114032B1 (fr)
JP (1) JP3561474B2 (fr)
KR (1) KR100422286B1 (fr)
CN (2) CN1318057A (fr)
AP (1) AP1345A (fr)
AR (1) AR030523A1 (fr)
AT (1) ATE268324T1 (fr)
AU (1) AU747715B2 (fr)
BG (1) BG65101B1 (fr)
BR (1) BR9913855A (fr)
CA (1) CA2344248C (fr)
CO (1) CO5290250A1 (fr)
CR (1) CR6306A (fr)
CU (1) CU23053A3 (fr)
CZ (1) CZ2001954A3 (fr)
DE (1) DE69917790T2 (fr)
DK (1) DK1114032T3 (fr)
DZ (1) DZ2891A1 (fr)
EA (1) EA005761B1 (fr)
EE (1) EE200100167A (fr)
ES (1) ES2221420T3 (fr)
GC (1) GC0000108A (fr)
GE (1) GEP20032973B (fr)
GT (1) GT199900147A (fr)
HK (1) HK1039938A1 (fr)
HR (1) HRP20010200B1 (fr)
HU (1) HUP0103512A3 (fr)
ID (1) ID27838A (fr)
IL (1) IL141388A0 (fr)
IS (1) IS2278B (fr)
MA (1) MA26689A1 (fr)
MY (1) MY121405A (fr)
NO (1) NO319781B1 (fr)
NZ (1) NZ509837A (fr)
OA (1) OA11651A (fr)
PA (1) PA8481201A1 (fr)
PE (1) PE20001054A1 (fr)
PL (1) PL198124B1 (fr)
PT (1) PT1114032E (fr)
SI (1) SI1114032T1 (fr)
SK (1) SK3532001A3 (fr)
SV (1) SV1999000150A (fr)
TN (1) TNSN99170A1 (fr)
TR (1) TR200100780T2 (fr)
TW (1) TW502022B (fr)
UA (1) UA70960C2 (fr)
WO (1) WO2000017165A1 (fr)
YU (1) YU18101A (fr)
ZA (1) ZA200101745B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
EP1385501A2 (fr) * 2001-04-11 2004-02-04 Atherogenics, Inc. Procedes d'accroissement des taux de cholesterol hdl du plasma et d'amelioration de la fonctionnalite hdl avec des monoesters de probucol
ES2259080T3 (es) * 2001-04-30 2006-09-16 Pfizer Products Inc. Procedimientos e intermedios para preparar inhibidores cetp.
CZ20033341A3 (cs) * 2001-06-21 2004-10-13 Pfizeráproductsáinc Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
TNSN03138A1 (fr) * 2001-06-22 2005-12-23 Pfizer Prod Inc Compositions pharmaceutiques d'adsorbats d'un medicament amorphe
ATE444060T1 (de) 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
WO2003053359A2 (fr) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
AU2002351748B2 (en) * 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
EP1469833B1 (fr) * 2002-02-01 2021-05-19 Bend Research, Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
DE60322665D1 (de) * 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
CA2474838C (fr) 2002-02-01 2009-01-06 Pfizer Products Inc. Compositions pharmaceutiques de dispersions amorphes de medicaments et materiaux formant des microphases lipophiles
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
KR101116627B1 (ko) * 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60305724T2 (de) * 2002-10-21 2006-11-09 Warner-Lambert Co. Llc Tetrahydrochinolin-derivate als crth2 antagonisten
AU2003289207A1 (en) * 2002-12-06 2004-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
BR0317521A (pt) 2002-12-20 2005-11-16 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
EP1435356A1 (fr) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Dérivés de la quinoléine en tant qu'antagonistes de CRTH2
WO2004072042A2 (fr) * 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite de recepteurs nucleaires
MXPA05009848A (es) 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CN1795177A (zh) * 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
BRPI0414822A (pt) 2003-09-26 2006-11-14 Japan Tobacco Inc método de inibir a produção de lipoproteìna remanescente
WO2005033082A2 (fr) * 2003-09-30 2005-04-14 Pfizer Products Inc. Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
EP1670768B1 (fr) 2003-10-08 2009-09-09 Eli Lilly And Company Composes et techniques de traitement de la dyslipidemie
DE602004020649D1 (de) * 2003-11-07 2009-05-28 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
JP2007530550A (ja) 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
WO2006012093A1 (fr) * 2004-06-24 2006-02-02 Eli Lilly And Company Composés et procédés destinés à traiter la dyslipidémie
KR100859223B1 (ko) * 2004-06-24 2008-09-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2006004903A2 (fr) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006026469A2 (fr) 2004-08-25 2006-03-09 Essentialis, Inc. Formulations pharmaceutiques d'activateurs de canaux potassiques atp, et utilisations correspondantes
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006033004A1 (fr) * 2004-09-23 2006-03-30 Pfizer Products Inc. Composes de quinoline en tant qu'inhibiteurs de cetp
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006069162A1 (fr) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Nouveaux composes heterocycliques et leurs compositions pharmaceutiques
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
EP1844078B1 (fr) 2005-02-03 2016-09-28 Bend Research, Inc Compositions pharmaceutiques a efficacite amelioree
AU2006216713A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
EP2985022B1 (fr) * 2005-07-01 2018-09-12 Merck Sharp & Dohme Corp. Procédé de synthèse d'un inhibiteur de cetp
WO2007006761A1 (fr) * 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkylcarbamoylurées en tant qu’activateurs de glucokinase
EP1904466A1 (fr) * 2005-07-08 2008-04-02 Novo Nordisk A/S Activateurs de dicycloalkylurée glucokinase
CN101263131B (zh) * 2005-07-14 2013-04-24 特兰斯特克药品公司 脲葡糖激酶活化剂
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
WO2007048027A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Combinaison de composes organiques
WO2007054896A1 (fr) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d’acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP3545958A1 (fr) 2006-01-05 2019-10-02 Essentialis, Inc. Sels d'ouverture de canal atp du potassium et leurs utilisations
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
GB0615670D0 (en) * 2006-08-07 2006-09-13 Syngenta Participations Ag Chemical compounds
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
AR063275A1 (es) * 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2008079398A1 (fr) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
EP2099777B1 (fr) * 2007-01-11 2015-08-12 Novo Nordisk A/S Activateurs de l'urée glucokinase
CN101220021B (zh) * 2007-01-12 2010-12-08 上海医药工业研究院 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
AU2008241904B2 (en) 2007-04-13 2012-06-07 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
AU2008324243B2 (en) 2007-11-05 2012-03-08 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PL2404901T3 (pl) 2007-12-03 2013-10-31 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
AU2008335135A1 (en) 2007-12-11 2009-06-18 Cytopathfinder, Inc. Carboxamide compounds and their use as chemokine receptor agonists
WO2010130773A2 (fr) 2009-05-15 2010-11-18 Novartis Ag Dérivés de benzoxazolone en tant qu'inhibiteurs d'aldostérone synthase
MX2011012198A (es) 2009-05-15 2011-12-08 Novartis Ag Aril-piridinas como inhibidoras de sintasa de aldosterona.
ES2602902T3 (es) 2009-05-28 2017-02-22 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
EP3048100A1 (fr) 2009-05-28 2016-07-27 Novartis AG Dérivés aminobutyriques substitués en tant qu'inhibiteurs de la néprilysine
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
EP2501678B1 (fr) 2009-11-17 2015-09-23 Novartis AG Dérivés de l'arylpyridine comme inhibiteurs de l'aldosterone synthase.
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (fr) 2009-11-30 2014-03-12 Novartis AG Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase
EP2571860A1 (fr) 2010-05-21 2013-03-27 Pfizer Inc 2-phénylbenzoylamides
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2668507B1 (fr) 2011-01-26 2017-08-23 INSERM - Institut National de la Santé et de la Recherche Médicale Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
AU2012271661B8 (en) 2011-06-17 2016-11-10 Merck Sharp & Dohme Corp. Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2016032324A1 (fr) * 2014-08-28 2016-03-03 Dezima Pharma B.V. Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
US9931372B2 (en) 2015-01-23 2018-04-03 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
MA54261A (fr) 2019-01-18 2022-04-27 Astrazeneca Ab Inhibiteurs de pcsk9 et leurs procédés d'utilisation
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
WO2000038722A1 (fr) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES

Also Published As

Publication number Publication date
ATE268324T1 (de) 2004-06-15
AU747715B2 (en) 2002-05-23
GC0000108A (en) 2005-06-29
IS5858A (is) 2001-02-23
UA70960C2 (uk) 2004-11-15
EA005761B1 (ru) 2005-06-30
CO5290250A1 (es) 2003-06-27
ID27838A (id) 2001-04-26
TW502022B (en) 2002-09-11
EA200100249A1 (ru) 2001-08-27
AR030523A1 (es) 2003-08-27
SV1999000150A (es) 2000-06-06
CA2344248C (fr) 2007-01-09
KR100422286B1 (ko) 2004-03-11
OA11651A (en) 2004-12-07
PT1114032E (pt) 2004-09-30
CA2344248A1 (fr) 2000-03-30
BG65101B1 (bg) 2007-02-28
PA8481201A1 (es) 2000-09-29
CZ2001954A3 (cs) 2001-12-12
BR9913855A (pt) 2001-07-24
CU23053A3 (es) 2005-06-24
HUP0103512A3 (en) 2002-03-28
HRP20010200A2 (en) 2002-04-30
AP2001002100A0 (en) 2001-03-31
JP2002526476A (ja) 2002-08-20
HK1039938A1 (zh) 2002-05-17
ES2221420T3 (es) 2004-12-16
NO20011349D0 (no) 2001-03-16
EP1114032A1 (fr) 2001-07-11
KR20010085814A (ko) 2001-09-07
CN1515259A (zh) 2004-07-28
SI1114032T1 (fr) 2004-12-31
WO2000017165A1 (fr) 2000-03-30
NO319781B1 (no) 2005-09-12
PL198124B1 (pl) 2008-05-30
PE20001054A1 (es) 2000-10-14
AP1345A (en) 2004-12-15
DE69917790T2 (de) 2005-06-09
IS2278B (is) 2007-09-15
TR200100780T2 (tr) 2001-07-23
NO20011349L (no) 2001-05-14
BG105429A (en) 2001-12-29
HRP20010200B1 (en) 2006-10-31
SK3532001A3 (en) 2001-12-03
TNSN99170A1 (fr) 2005-11-10
CR6306A (es) 2003-08-28
DK1114032T3 (da) 2004-08-16
GT199900147A (es) 1999-09-06
MA26689A1 (fr) 2004-12-20
EE200100167A (et) 2002-06-17
ZA200101745B (en) 2002-05-02
HUP0103512A2 (hu) 2002-02-28
PL346830A1 (en) 2002-02-25
US6140343A (en) 2000-10-31
CN1318057A (zh) 2001-10-17
AU5440399A (en) 2000-04-10
DE69917790D1 (de) 2004-07-08
GEP20032973B (en) 2003-05-27
YU18101A (sh) 2004-05-12
JP3561474B2 (ja) 2004-09-02
IL141388A0 (en) 2002-03-10
EP1114032B1 (fr) 2004-06-02
US6489478B1 (en) 2002-12-03
NZ509837A (en) 2002-11-26
MY121405A (en) 2006-01-28

Similar Documents

Publication Publication Date Title
DZ2891A1 (fr) Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr) Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr) Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2963A1 (fr) Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr) Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr) Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr) Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr) Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr) Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr) Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr) Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr) Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr) Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr) Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr) 4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2634A1 (fr) Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr) Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2880A1 (fr) Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2457A1 (fr) Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2227A1 (fr) Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.